Appraisals - ASAR & FAR

26/02/2020

Appraisal Report: vandetanib (Caprelsa) 427

24/02/2020

Appraisal Report: valsartan (Diovan) 671

01/08/2019

Appraisal Report: ulipristal acetate (Esmya) 2767

25/07/2019

Appraisal Report: triamcinolone hexacetonide 2527

25/02/2020

Appraisal Report: travoprost (Travatan) 2601 ASAR

25/02/2020

Appraisal Report: tocilizumab (RoActemra) 1851

27/01/2022

Appraisal Report: tirbanibulin (Klisyri) 4076

25/07/2019

Appraisal Report: tiotropium (Spiriva Respimat) 1882

25/07/2019

Appraisal Report: telotristat ethyl (Xermelo) 2037

19/08/2019

Appraisal Report: tapentadol prolonged release (PalexiaSR) 651

25/02/2020

Appraisal report: tacrolimus (Envarsus) 2586

25/07/2019

Appraisal Report: stiripentol (Diacomit) 3468

25/07/2019

Appraisal Report: semaglutide (Ozempic) 1842

27/06/2019

Appraisal Report: rufinamide (Inovelon) 991

24/02/2020

Appraisal Report: rosuvastatin (Crestor) 679

26/06/2019

Appraisal Report: romiplostim (Nplate) 3103

24/02/2020

Appraisal Report: rolapitant (Varuby) 1303

31/08/2022

Appraisal Report: rituximab (MabThera) 3192

21/02/2020

Appraisal Report: riociguat (Adempas) 558

25/02/2020

Appraisal Report: riociguat (Adempas) 1608